Drug-induced autoimmune thyroiditis during lorlatinib treatment in a patient with ALK-positive non-small cell lung cancer
{{output}}
Lorlatinib has demonstrated significant efficacy for treating anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC); however, its safety profile-particularly regarding immune-related adverse events-remains incompletely characterized. We ... ...
